University of Copenhagen

ku.dk

Total trials

453

Active

45

Phase 3

5

Total enrollment

4,361,749

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 6 of 6 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Insulin2
Salmeterol2
Salmeterol inhalation and urine samples1
Salmeterol + amino acid availability1
Salmeterol + placebo1
Rapamycin1

Next readouts

  • 2022-12
  • 2026-12-18
  • 2026-12-31
  • 2026-12-31
  • 2029-06

Top conditions

  • Obesity69
  • Healthy42
  • Metabolic Syndrome19
  • Cardiovascular Disease13
  • Overweight12
  • Insulin Resistance12
  • Type 2 Diabetes10
  • Insulin Sensitivity10

Frequently asked questions about University of Copenhagen

How many clinical trials does University of Copenhagen have on ClinicalTrials.gov?
University of Copenhagen is listed as the lead sponsor on 453 clinical trials in ClinicalTrials.gov, 45 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Copenhagen's trials are in Phase 3?
5 of University of Copenhagen's trials are in Phase 3, spread across 6 active drug programs.
What therapeutic areas does University of Copenhagen focus on?
University of Copenhagen's most-studied conditions on ClinicalTrials.gov are Obesity, Healthy, Metabolic Syndrome, Cardiovascular Disease, Overweight.
When are University of Copenhagen's next clinical trial readouts?
University of Copenhagen has 5 upcoming primary-completion readouts tracked here; the soonest is “Insulin Sensitivity After Breast Cancer”, expected around 2022-12.